These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34987612)

  • 1. Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy.
    Peng J; Liu Y; Li W; Lin Y; Sun H; Pan Z; Wu X; Fan W; Lin J
    Therap Adv Gastroenterol; 2021; 14():17562848211066206. PubMed ID: 34987612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel score system for predicting conversion to no evidence of Disease (C-NED) in initially unresectable colorectal cancer liver metastases.
    Li W; Zhou J; Zhang T; Tai Y; Xu Y; Bai Y; Jiang Y; Lu Z; Li L; Huang J; Pan Z; Wu X; Peng J; Lin J
    Am J Cancer Res; 2022; 12(4):1648-1659. PubMed ID: 35530285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of total tumor volume reduction ratio in initially unresectable colorectal liver metastases after first-line systemic treatment.
    He J; Li W; Zhou J; Sun H; Zhou C; Liu Y; Quan T; Fan W; Pan Z; Lin J; Peng J
    Eur J Radiol; 2023 Aug; 165():110950. PubMed ID: 37437437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic factors affecting the success of conversion chemotherapy in patients with unresectable liver metastases from initially colorectal cancer].
    Zhang WL; Zhou C; Deng YX; Hou ZL; Zhang LJ; Lin JZ; Pan ZZ; Lu ZH; Peng JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jan; 25(1):56-62. PubMed ID: 35067035
    [No Abstract]   [Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy weakens the prognostic value of the pathological tumor burden score for colorectal cancer liver metastases.
    Liao L; Sun H; He J; Liu Y; Pan Z; Wu X; Fan W; Peng J; Li C
    BMC Surg; 2023 Sep; 23(1):271. PubMed ID: 37689651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score.
    Yonekawa Y; Uehara K; Mizuno T; Aiba T; Ogura A; Mukai T; Yokoyama Y; Ebata T; Kodera Y; Nagino M
    Int J Clin Oncol; 2021 Jan; 26(1):126-134. PubMed ID: 33074351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic utility of the "Tumor Burden Score" based on preoperative radiographic features of colorectal liver metastases.
    Sasaki K; Margonis GA; Andreatos N; Zhang XF; Buettner S; Wang J; Deshwar A; He J; Wolfgang CL; Weiss M; Pawlik TM
    J Surg Oncol; 2017 Sep; 116(4):515-523. PubMed ID: 28543544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Tumor Burden Score: A New "Metro-ticket" Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors.
    Sasaki K; Morioka D; Conci S; Margonis GA; Sawada Y; Ruzzenente A; Kumamoto T; Iacono C; Andreatos N; Guglielmi A; Endo I; Pawlik TM
    Ann Surg; 2018 Jan; 267(1):132-141. PubMed ID: 27763897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.
    Tsilimigras DI; Hyer JM; Bagante F; Guglielmi A; Ruzzenente A; Alexandrescu S; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
    J Am Coll Surg; 2021 Apr; 232(4):590-598. PubMed ID: 33383214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylated ctDNA predicts early recurrence risk in patients undergoing resection of initially unresectable colorectal cancer liver metastases.
    Chen ZG; Ji XM; Xu YX; Fong WP; Liu XY; Liang JY; Tan Q; Wen L; Cai YY; Wang DS; Li YH
    Ther Adv Med Oncol; 2024; 16():17588359241230752. PubMed ID: 38425989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer.
    Peng J; Li W; Fan W; Zhang R; Li X; Xiao B; Dong Y; Wan D; Pan Z; Lin J; Wu X
    Cancer Cell Int; 2021 Oct; 21(1):554. PubMed ID: 34688293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of margin status and tumour burden determines survival after resection of colorectal liver metastases: A retrospective cohort study.
    Mao R; Zhao JJ; Bi XY; Zhang YF; Li ZY; Zhou JG; Zhao H; Cai JQ
    Int J Surg; 2018 May; 53():371-377. PubMed ID: 29229309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parenchymal-sparing hepatectomy for colorectal liver metastases reduces postoperative morbidity while maintaining equivalent oncologic outcomes compared to non-parenchymal-sparing resection.
    Andreou A; Gloor S; Inglin J; Di Pietro Martinelli C; Banz V; Lachenmayer A; Kim-Fuchs C; Candinas D; Beldi G
    Surg Oncol; 2021 Sep; 38():101631. PubMed ID: 34298267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation.
    Chen Y; Chang W; Ren L; Chen J; Tang W; Liu T; Jian M; Liu Y; Wei Y; Xu J
    Oncologist; 2020 Jul; 25(7):e1031-e1041. PubMed ID: 32181531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review.
    Bolhuis K; Kos M; van Oijen MGH; Swijnenburg RJ; Punt CJA
    Eur J Cancer; 2020 Dec; 141():225-238. PubMed ID: 33189037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor burden score is superior to primary liver cancer stages in predicting prognosis for patients with combined hepatocellular-cholangiocarcinoma after surgery: A multi-center study.
    Jiang C; Qin F; Yan J; Zou J; Wang H; Zhang H; Feng X; Hou G
    Eur J Surg Oncol; 2024 Nov; 50(11):108610. PubMed ID: 39213695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher Tumor Burden Neutralizes Negative Margin Status in Hepatectomy for Colorectal Cancer Liver Metastasis.
    Oshi M; Margonis GA; Sawada Y; Andreatos N; He J; Kumamoto T; Morioka D; Wolfgang CL; Tanaka K; Weiss MJ; Endo I
    Ann Surg Oncol; 2019 Feb; 26(2):593-603. PubMed ID: 30483976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kirsten rat sarcoma (KRAS) oncogene mutation predicts magnitude of response and outcomes in hepatic arterial infusion pump therapy of unresectable colorectal liver metastases.
    Kolbeinsson HM; Preihs R; Bengel A; Chandana S; Assifi MM; Chung MH; Wright GP
    J Gastrointest Oncol; 2022 Feb; 13(1):163-170. PubMed ID: 35284135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion therapy combined with individualized surgical treatment strategy improves survival in patients with colorectal cancer liver metastases.
    Ma R; Li T
    Int J Clin Exp Pathol; 2021; 14(3):314-321. PubMed ID: 33786148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating Efficacy of Conversion Therapy on Patients with Initially Unresectable Colorectal Cancer Liver Metastases by using MRI: Development of a Predictive Score.
    Liu J; Tang W; Ye L; Miao G; Zeng M; Liu L
    Acad Radiol; 2024 Nov; 31(11):4478-4487. PubMed ID: 38734578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.